A recent study by William Rutala, PhD, MPH, published in the November 2012 issue of Infection Control and Hospital Epidemiology, showed that healthcare disinfectants containing improved hydrogen peroxide had greater efficacy than standard hydrogen peroxide or quaternary ammonium chloride (quat) disinfectants against community acquired methicillin-resistant Staphylococcus aureus (CA-MRSA), vancomycin-resistant Enterococcus (VRE) and multidrug-resistant (MDR) Acinetobacter baumannii. Diversey’s Oxivir® Tb, based on patented AHP technology , is one of the improved hydrogen peroxide products referenced in the study. The Oxivir Tb product is further differentiated in the market by having the best safety profile possible for a disinfectant.
“Numerous published studies have shown that environmental contamination plays a role in the transmission of healthcare-associated pathogens including MRSA, VRE, and MDR A. baumannii,” says Carolyn Cooke, vice president of the healthcare sector at Diversey, now part of Sealed Air. “This research demonstrates that Oxivir Tb, which has an excellent safety and environmental profile, offered exceptional efficacy at 30 seconds and 1-minute contact times against key pathogens commonly found in the healthcare environment.”
AHP-based products, such as Oxivir Tb, are the only improved hydrogen peroxide disinfectants currently on the market that provide this combination of efficacy and safety. In all six EPA toxicity studies, Oxivir Tb falls into the category with lowest level of hazard, creating a safer environment for staff and patients.
Diversey’s Oxivir line of products were introduced in 2006 to provide an alternative to traditional disinfectants by delivering fast acting, broad spectrum disinfection, with enhanced cleaning power that is friendly to staff, patients and surfaces. The active ingredient breaks down into oxygen and water within minutes after application.
Diversey is a business of Sealed Air Corp., a leader in food safety and security, facility hygiene and product protection.